Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Association of Adiponectin Genotypes With Colorectal Cancer Susceptibility in Taiwan

YI-CHIH HUNG, WEN-SHIN CHANG, AN-KUO CHOU, JEN-SHENG PEI, MEI-DUE YANG, HORNG-REN YANG, TA-MING YANG, YUN-CHI WANG, YU-CHEN HSIAU, CHOU-PIN CHEN, CHOU-CHEN CHEN, CHIEN-CHIH YU, CHIA-WEN TSAI and DA-TIAN BAU
Anticancer Research March 2020, 40 (3) 1297-1306; DOI: https://doi.org/10.21873/anticanres.14071
YI-CHIH HUNG
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
2Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEN-SHIN CHANG
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AN-KUO CHOU
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
4Department of Anesthesiology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JEN-SHENG PEI
5Department of Pediatrics, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MEI-DUE YANG
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HORNG-REN YANG
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TA-MING YANG
6Department of Surgery, Tainan Municipal Hospital, Tainan, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUN-CHI WANG
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU-CHEN HSIAU
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHOU-PIN CHEN
7Department of Surgery, Division of Colorectal, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHOU-CHEN CHEN
7Department of Surgery, Division of Colorectal, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIEN-CHIH YU
8School of Pharmacy, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
CHIA-WEN TSAI
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
DA-TIAN BAU
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
3Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
9Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To investigate the association between adiponectin (ADIPOQ) genotypes and colorectal cancer (CRC) risk among Taiwanese. Materials and Methods: Polymerase chain reaction–restriction fragment length polymorphism was adopted to identify ADIPOQ rs266729, rs2241766 and rs1501299 genotypes among 362 CRC patients and 362 healthy controls. Results: ADIPOQ rs266729 GG genotype (p=0.0075) and G allele (p=0.0061) are associated with a significantly increased CRC risk. There is no differential distribution of rs2241766 and rs1501299 genotypes. As for the gene–lifestyle interaction, there are obvious joint effects of rs266729 genotype on the CRC risk among non-smoker, non-alcohol drinker, while not on smoker or non-drinker subgroups. No significant correlation was observed between rs266729 genotypic distributions and age, gender, tumor size, location or metastasis status. Interestingly, a correlation of rs266729 genotype and larger BMI on CRC risk was found. Conclusion: G allele at ADIPOQ rs266729 may serve as a determiner for CRC risk, especially for those with BMI ≥24.

  • ADIPOQ
  • colorectal cancer
  • genotype
  • polymorphism
  • Taiwan

Colorectal cancer (CRC), the third most common cancer among men and the second among women, has been reported to be closely related to human morbidity and mortality worldwide (1-3). Interestingly, the incidence and mortality rates of CRC vary dramatically around the world with regional differences that can reach as high as ten-fold (2-4). Scientists in epidemiology attributed about 85% of CRC etiology to environmental factors, such as meat consumption, cigarette smoking, and exposure to carcinogens (5, 6). On the other hand, at least 15-20% of CRC cases, those with strong familial cancer history have attracted molecular epidemiologists to figure out the contributions of genomic susceptibility genotypes (7-9). In Taiwan, the incidence and mortality rates of CRC has been listed as the first and third cancer among the common types of cancer for decades and the extremely high incidence has been owed to the dietary alterations toward Western diet style and the decreasing consumption of fibers or grain-made foods. Although specific biomarkers for CRC prediction and detection have been reported within recent years (10-14), the interactions among the genomic, demographic and environmental risk factors remain largely unrevealed (15). Etiologically speaking, genomic, demographic and environmental factors team-up to play a significant role in the pathogenesis of CRC (16). CRC has been identified as an obesity-related malignancy (17). Certain epidemiological investigations have proposed that Western dietary styles and behavioral patterns, such as high-fat and low-fiber intake, low daily physical activity for more than half year, which leads to obesity, insulin resistance and hypertension, are the major determiners for the increasing CRC incidence, particularly in developing countries such as Taiwan (18, 19). In the post genomic era, the biomarker-guided personalized therapy for CRC shall play a more important role (20).

Adiponectin (ADIPOQ), which is exclusively secreted from adipocytes, is an anti-atherosclerosis, anti-inflammation and insulin-sensitizing adipokine (18, 19). In the literature, decreased levels of ADIPOQ in the circula tion have been observed in a panel of cancers including gastric cancer (21), pancreatic cancer (22), breast cancer (23) endometrial cancer (24), and most of all, colorectal cancer (25). However, the results are contro versial in the case of pancreatic cancer, since Dalamaga and colleagues found that serum ADIPOQ levels had a posi tive association with pancreatic cancer risk (26). This kind of inconclusiveness may also be found in CRC, which reminds us that the contribution of ADIPOQ to the elevated risk for cancer are cancer-specific and different among various ethnics.

As far as CRC is concerned, the asso ciations between obesity, lectin, ADIPOQ with CRC risk have been revealed in several epidemio logical investigations (17, 27, 28), however, no genomic marker is currently available for early diagnosis and prognosis. Although the function of about 600 polymorphic genotypes remains unrevealed, three of the commonly examined single nucleotide polymorphisms (SNPs) on ADIPOQ, rs2241766 (45T/G), rs266729 (-11377C/G) and rs1501299 (276G/T), are found to be determiners for the personal susceptibility for several human diseases including squamous cell esophageal cancer (29), non-alcoholic fatty liver disease (30), coronary heart disease (31) and type-2 diabetes mellitus (32). Supporting this idea, several groups have provided evidence that the people carrying the variant genotypes of these polymorphic sites have different levels of ADIPOQ in their blood (33), insulin resis tance and obesity status (34), and CRC susceptibility compared to those carrying the wild-type genotype (18, 35). At the same time, several other groups present controversial findings (36, 37). To confirm the contributions of genotypes of ADIPOQ to CRC, we conducted a hospital-based case-control study to evaluate the three SNPs of ADIPOQ, rs2241766, rs266729 and rs1501299, regarding their possibility to serve as a predictor for CRC risk in Taiwan population.

Materials and Methods

Investigated CRC cases and controls. The investigated population included 362 CRC patients and 362 controls and the methodology has been described in our previous studies (10-13). Briefly, CRC patients who had visited our hospital were recruited at the outpatient clinics of general surgery. The pathological-clinical indexes of each patient were defined, graded and recorded by expert surgeons (38, 39). A 1:1 of non-cancer healthy people were selected as controls by matching for age, gender and some indulgences after initial random sampling from the Health Examination Cohort of the Hospital with the help of colleagues in the Department of Family Medicine. The exclusion criteria of the control group included previous malignancy, metastasized cancer from other or unknown origin and any familial or genetic diseases. All participants have completed a self-administered questionnaire and provided a 5-ml sample of peripheral blood for genotyping. This study was approved by the Institutional Review Board of the China Medical University Hospital (IRB project identification coding number: DMR99-IRB-108) and written informed consent was obtained from all the participants with the help of Tissue Bank of China Medical University Hospital. The selective demographic information of the participants is summarized in Table I.

Procedures for ADIPOQ genotyping. Genomic DNA was extracted from the peripheral blood leukocytes of each subject within 24 h with a QIAamp Blood Mini Kit (Qiagen, Chatsworth, CA, USA), stored long-term at −80°C, diluted and aliquoted for genotyping as a working stock at −20°C as previously described (40-43). Consulting the NCBI database (www.ncbi.nlm.nih.gov/snp), we obtained three of the SNPs out of more than 600 of ADIPOQ, rs2241766, rs266729 and rs1501299, for the Han Chinese with the criteria of minor allele frequency ≥0.05 and r2 ≥0.8. The typical polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) technology was adopted to determine ADIPOQ rs2241766, rs266729 and rs1501299 genotypes. Concisely, the polymerase chain reaction (PCR) cycling conditions were: one cycle at 94°C for 5 min; 35 cycles of 94°C for 30 s, 59°C for 30 s and 72°C for 30 s, and a final extension at 72°C for 10 min. The genotyping PCR for ADIPOQ rs2241766 was conducted using the forward 5’-GAA GTA GAC TCT GCT GAG AT-3’ and the reverse 5’-TAT CAG TGT AGG AGG TCTGT-3’ primer pairs. The genotyping PCR for ADIPOQ rs266729 was conducted using the forward 5’-GCT CTG TGT GGA CTG TGG AG-3’ and the reverse 5’-AGA AGC AGC CTG GAG AAC TG-3’ primer pairs. The genotyping PCR for ADIPOQ rs1501299 was conducted using the forward 5’-TGG TCC TTT GGT GCT GAG TT-3’ and the reverse 5’-TAC GCC AAG CTT TGC TTT CT-3’ primer pairs. The obtained PCR products of ADIPOQ rs2241766, rs266729 and rs1501299 were then digested with SmaI, SapI and BsmI, respectively, and identified of individual genotype after 3% agarose gel electrophoresis. All the genotypic processing was repeated by two expert researchers independently and blindly, and their results were 100% concordant to each other. In addition, the success rate of PCR-restrictive fragment length polymorphism (RFLP) is 100%, and the genotypes of 5% of the participants in both the control and CRC patient groups were analyzed by PCR direct sequencing (Genomics BioSci & Tech Co). The concordance between direct sequencing and PCR-RFLP methods was 100%.

Statistical analysis. The Student's t-test was applied for the comparison of ages between the CRC cases and the control groups. The fitness of Hardy–Weinberg equilibrium for the control group were performed with the Chi-square test. Pearson's Chi-square or Fisher's exact test (when any cell analyzed was less than 5, such as that in Table V, right panel) was applied to compare the distribution of the ADIPOQ genotypes among the subgroups. The associations between ADIPOQ genotypes and CRC risk were estimated by computing odds ratios (ORs) and their 95% confidence intervals (CIs) from logistic regression analysis. Statistically, any difference at p<0.05 was taken as significant between the two groups compared.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Summary of selected data from 362 patients with colorectal cancer and 362 matched non-cancer healthy controls.

Results

The distributions of age, gender and BMI for the 362 CRC patients and 362 non-cancer healthy controls are presented in Table I (Table I, top panel). In addition, the tumor size, occurred location, and lymph node involvement are also summarized in Table I (Table I, bottom panel). Since we adopted the frequency matching methodology to include those non-cancer healthy citizens as controls, the statistical results showed that there was no difference in respect to the distribution of age and gender between the control and case groups (both p>0.05) (Table I, top panel). CRC patients with small (<5 cm) and large (≥5 cm) tumor sizes were 195 (53.9%) and 167 (46.1%), respectively. CRC patients with tumor location at colon and rectum were 257 (71.0%) and 105 (29.0%), respectively. CRC patients with and without lymph node involvement were 152 (42.0%) and 210 (58.0%), respectively (Table I, bottom panel).

The distribution of ADIPOQ rs2241766, rs266729 and rs1501299 genotypic frequencies among the 362 non-cancer healthy controls and the 362 CRC patients are presented in Table II. First, in the Hardy-Weinberg equilibrium examination, the results showed that all ADIPOQ rs2241766, rs266729 and rs1501299 genotypic frequencies in the control group complied well with the Hardy-Weinberg equilibrium (all p>0.05). Secondly, the results showed that the genotypes of ADIPOQ rs2241766 among Taiwanese were not differently distributed between the case and the control groups (p for trend=0.6148) (Table II, top panel). Thirdly, the genotypes of ADIPOQ rs266729 were differently distributed between the case and the control groups (p for trend=0.0233) (Table II, middle panel). In detail, the ADIPOQ rs266729 homozygous variant GG but not the heterozygous CG was associated with increased CRC risk, compared with the wild-type CC genotype (p=0.0075 and 0.1829, respectively; Table II middle panel). After being adjusted for confounding factors age, gender, smoking, alcohol and betel quid consumption, and BMI status, the ORs for homozygous variant GG and the heterozygous CG were 1.94 and 1.22, respectively (95%CI=1.23-1.98 and 0.91-1.64). In the dominant analyzing model, there was still an association between the combined CG+GG of ADIPOQ rs266729 and CRC risk, compared with CC wild-type genotype (adjusted OR=1.63, 95%CI=1.14-1.93, p=0.0001, Table II middle panel). Last, the genotypes of ADIPOQ rs1501299 were not differently distributed between the case and the control groups (p for trend=0.8921), either (Table II, bottom panel).

In order to validate the findings in Table II, the analysis of allelic frequency distribution for the ADIPOQ rs2241766, rs266729 and rs1501299 was further conducted and the results are shown in Table III. Consistent with the findings that genotype of ADIPOQ rs266729 was associated with CRC risk, the variant allele G was found at 33.7% in the case group, significantly higher than that of 27.1% in the control group (p=0.0061) (Table III, middle panel). At the same time, there was no such difference found in the analysis for ADIPOQ rs2241766 and rs1501299 (Table III, top and bottom panels).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Distribution of ADIPOQ rs2241766, rs266729 and rs1501299 genotypic frequencies among colorectal cancer patients and healthy controls

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Allelic frequencies for ADIPOQ rs2241766, rs266729 and rs1501299 polymorphisms among colorectal cancer patients and healthy controls.

Demographic variables, such as age, gender, familial CRC history, diets high in calories and animal fat, alcohol consumption, and obesity, in addition to other factors, such as tumor site, size, grade, histologic type, TNM stage, and carcinoembryonic antigen (CEA) level, have all been found to significantly affect survival in CRC (44-47). Since smoking and alcohol drinking habits are well-known risk factors for CRC in Taiwan, we were interested in investigating the interactions between the genotype of ADIPOQ rs266729 with personal cigarette smoking and alcohol drinking status. Firstly, among those non-smokers, people with ADIPOQ rs266729 CG and GG genotypes were at 1.16- and 1.87-fold odds of having CRC (95%CI=0.81-1.67 and 1.06-3.32, p=0.4017 and 0.0297, respectively) conferring risky effect, while a non-significant effect was observed in the case for those smokers (Table IV). After adjusting for age, gender, alcohol drinking, betel quid chewing and BMI status, the statistical significance still existed at a similar level (Table IV, left panel). Secondly, among non-drinkers, those with CG and GG genotypes at ADIPOQ rs266729 were at 1.22- and 1.87-fold odds of having CRC (95%CI=0.87-1.70 and 1.09-3.20, p=0.2519 and 0.0208, respectively) conferring a risk effect, while a non-significant effect was observed among those drinkers (Table V). After adjusting for age, gender, smoking, betel quid chewing and BMI status, the results were still the same for both non-drinker and drinker groups (Table V).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Odds ratios for ADIPOQ rs266729 genotype and colorectal cancer after stratification by smoking status.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Odds ratios for ADIPOQ rs266729 genotype and colorectal cancer after stratification by alcohol drinking status.

The correlations between genotypes of ADIPOQ rs266729 and clinicopathological features among the 362 CRC patients were analyzed and the results are shown in Table VI. No statistically significant correlation was observed between ADIPOQ rs266729 genotypic distributions and age, gender, tumor size, location or metastasis status (all p>0.05) (Table VI). Interesting, the percentages of CG and GG genotypes of ADIPOQ rs266729 were statistically higher among the patients with larger BMI (≥24) than those with smaller BMI (<24) (p=0.0162) (Table VI, middle panel).

Discussion

In the literature, mounting epidemiological evidence has demonstrated that obesity may increase the risk of several types of cancer, including CRC (48-50). Some reports have also shown that in obese subjects, serum levels of ADIPOQ are much lower than those in non-obese (51, 52). It is reasonable to hypothesize that decreased levels of ADIPOQ in the blood may be associated with the increased risk for CRC (53-56), and furthermore, the genotypes of ADIPOQ may contribute to the association. Supporting this notion, it is reported that ADIPOQ may suppress the cell growth in preneoplastic colonic lesions via several molecules such as leptin and NF-κB (57). In the literature, several investigations have shown that specific genotypes of ADIPOQ were associated with the levels of ADIPOQ in human blood, such as ADIPOQ rs266729, rs1501299 and rs2241766 (58-60). Noticeably, the G allele at ADIPOQ rs266729 was significantly associated with lower ADIPOQ levels (61), and the lower ADIPOQ levels was associated with elevated CRC risk (54, 55).

In the current study, we firstly examined the contribution of ADIPOQ rs266729, rs1501299 and rs2241766 genotypes to CRC susceptibility in Taiwan, where CRC is the highest prevalent cancer in the country for many years. The results showed that the genotypes of ADIPOQ rs266729, which locates at the promoter region of the genes and is most likely to determine the expression level of it, are associated with risk of CRC in Taiwan (Table II). Noticeably, the GG genotype and the G allele of ADIPOQ rs266729 were significantly associated with elevated risk to CRC (Tables II and III). At the same time, there was no significant association as for the genotypes at ADIPOQ rs1501299 or rs2241766 with CRC for Taiwanese (Tables II and III). As far as we are aware of, the current study is the first to reveal the genotypic contribution of ADIPOQ promoter genotypes to CRC in Taiwan and this positive finding is consistent with previous investigations in American (37), Germany (62), and Japanese (63) populations.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VI.

Correlation between ADIPOQ rs266729 genotypes and clinicopathological properties of 362 colorectal cancer patients.

As for the personal habits, we analyzed the interactions of ADIPOQ rs266729 genotype with smoking and alcohol drinking behaviors, finding that the genotypic contribution of ADIPOQ rs266729 genotype to CRC risk is more obvious among those non-smokers and non-alcohol drinkers, but not among those smokers or alcohol drinkers (Tables IV and V). The detailed mechanisms need further investigation. As for the clinical features, we did not find any correlation between the ADIPOQ rs266729 genotype with age, gender, tumor size, location or lymph node metastasis status, while there is synergistically an obvious interaction of ADIPOQ rs266729 and BMI (Table VI). It seems that those with BMI ≥24 and carrying G allele at ADIPOQ rs266729 in their genome may have higher risk of CRC. The detail mechanisms and the prognosis of these people are of our interest in further investigations in the near future.

In the future, there are several directions for us to conduct further studies investigating the contribution of ADIPOQ pathway in CRC. First, there are several other SNPs that may regulate the expression of activity of ADIPOQ, worthy of figuring out their roles in CRC (36). Secondly, we have to pay more attention to the receptors of ADIPOQ. ADIPOQ has been proposed as a biological link between obesity and various types of malignancies, such as CRC, through its actions mediated by binding and activating specific ADIPOQ receptors, ADIPOQ receptor 1 (AdipoR1) and ADIPOQ receptor 2 (AdipoR2) (64). These two types of ADIPOQ receptors have been identified to link ADIPOQ to the activation of adenosine monophos phate (AMP)-activated protein kinases, which help ADIPOQ to inhibit the proliferation of cancer cells (65). According to their differential distribution in the human body to conduct their individual functions, AdipoR1 and AdipoR2 are predominantly abundant in skeletal muscle cells and liver cells, respectively (66). AdipoR2 is a protein encoded by the AdipoR2 gene (67), in charge of mediating lots of metabolic processes such as oxidation of fatty acid and cell intake of glucose by ADIPOQ (68). Notably, the two types of ADIPOQ receptors are both reported to be expressed in human cancer cells, such as CRC, breast and prostate cancer, and mediate the anti-proliferative behaviors of ADIPOQ in these cancer cells (69). Supporting the idea that the ADIPOQ pathway indeed plays a critical role in CRC etiology, several single nucleotide polymorphisms (SNPs) on the ADIPOQ or its receptor genes, such as rs1342387 and rs1063538, were reported to associate with CRC risk (18, 35, 62, 69). From the genomic viewpoint, two polymorphic sites on the AdipoR2 gene, rs10773989 and rs1044471, have been reported to be associated with type-2 diabetes, prostate and gastric cancer (70-72). However, such associations between the polymorphic genotypes on AdipoR2 and CRC remain inconclusive (37, 73). In the future, we are going to examine the contribution of the genotypes of ADIPOQ receptors to CRC, and analyze the interactions of genotypes for ADIPOQ and ADIPOQ receptors on CRC.

In conclusion, this study investigated the contribution of ADIPOQ genotypes and their interaction with demographic and behavioral status to determine personal susceptibility to CRC. The GG genotypes of ADIPOQ rs266729 may cause a relatively low level of ADIPOQ in the blood, defect its suppressive influence on CRC cell growth and proliferation, and increase the personal risk of CRC, especially for those with BMI ≥24.

Acknowledgements

The Authors declare no conflicts of interest in regard to this study. We appreciate the Tissue-bank of China Medical University Hospital for their excellent technical assistance and all the subjects, doctors, nurses and colleagues. The technical help from Yu-Ting Chin, Tai-Lin Huang, Yu-Hsin Lin and Yi-Ru Huang are respected by all the authors. This study was supported mainly by China Medical University Hospital to Dr. Chou (DMR-109-091).

Footnotes

  • ↵* These Authors contributed equally to this study.

  • Authors' Contributions

    Research design: Hung YC, Pei JS, Chou AK; patient and questionnaire summaries: Yang MD, Yang HR; experimental work: Wang YC, Chang WS, Hsiau YC; statistical analysis: Yang TM, Chen CP, Chen CC, Yu CC; manuscript writing: Yu CC, Tsai CW, Bau DT; review & revision: Chang WS, Tsai CW, Yu CC, Bau DT.

  • Conflicts of Interest

    All the Authors have declared no conflicts of interest regarding this study.

  • Received January 18, 2020.
  • Revision received January 28, 2020.
  • Accepted February 3, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    : Cancer statistics, 2019. CA Cancer J Clin 69: 7-34, 2019. PMID: 30620402. DOI: 10.3322/caac.21551
    OpenUrlCrossRefPubMed
  2. ↵
    1. Arnold M,
    2. Sierra MS,
    3. Laversanne M,
    4. Soerjomataram I,
    5. Jemal A,
    6. Bray F
    : Global patterns and trends in colorectal cancer incidence and mortality. Gut 66: 683-691, 2017. PMID: 26818619. DOI: 10.1136/gutjnl-2015-310912
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Siegel RL,
    2. Torre LA,
    3. Soerjomataram I,
    4. Hayes RB,
    5. Bray F,
    6. Weber TK,
    7. Jemal A
    : Global patterns and trends in colorectal cancer incidence in young adults. Gut 68: 2179-2185, 2019. PMID: 31488504. DOI: 10.1136/gutjnl-2019-319511
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Douaiher J,
    2. Ravipati A,
    3. Grams B,
    4. Chowdhury S,
    5. Alatise O,
    6. Are C
    : Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol 115: 619-630, 2017. PMID: 28194798. DOI: 10.1002/jso.24578
    OpenUrl
  5. ↵
    1. Nagini S
    : Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 4: 156-169, 2012. PMID: 22844547. DOI: 10.4251/wjgo.v4.i7.156
    OpenUrlCrossRefPubMed
  6. ↵
    1. Jayasurya R,
    2. Sathyan KM,
    3. Lakshminarayanan K,
    4. Abraham T,
    5. Nalinakumari KR,
    6. Abraham EK,
    7. Nair MK,
    8. Kannan S
    : Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol 18: 1056-1066, 2005. PMID: 15731778. DOI: 10.1038/modpathol.3800387
    OpenUrlCrossRefPubMed
  7. ↵
    1. Butterworth AS,
    2. Higgins JP,
    3. Pharoah P
    : Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 42: 216-227, 2006. PMID: 16338133. DOI: 10.1016/j.ejca.2005.09.023
    OpenUrlCrossRefPubMed
    1. Houlston RS,
    2. Tomlinson IP
    : Polymorphisms and colorectal tumor risk. Gastroenterology 121: 282-301, 2001. PMID: 11487538. DOI: 10.1053/gast.2001.26265
    OpenUrlCrossRefPubMed
  8. ↵
    1. Rasool S,
    2. Rasool V,
    3. Naqvi T,
    4. Ganai BA,
    5. Shah BA
    : Genetic unraveling of colorectal cancer. Tumour Biol 35: 5067-5082, 2014. PMID: 24573608. DOI: 10.1007/s13277-014-1713-7
    OpenUrlCrossRefPubMed
  9. ↵
    1. Wu MH,
    2. Tzeng HE,
    3. Wu CN,
    4. Yueh TC,
    5. Peng YC,
    6. Tsai CH,
    7. Wang YC,
    8. Ke TW,
    9. Pei JS,
    10. Chang WS,
    11. Tsai CW,
    12. Bau DT
    : Association of matrix metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk. Anticancer Res 39: 6523-6529, 2019. PMID: 31810917. DOI: 10.21873/anticanres.13867
    OpenUrlAbstract/FREE Full Text
    1. Wu MH,
    2. Hung YW,
    3. Gong CL,
    4. Chao CC,
    5. Yueh TC,
    6. Wang SC,
    7. Lai YL,
    8. Hsu SW,
    9. Fu CK,
    10. Wang YC,
    11. Ke TW,
    12. Chang WS,
    13. Tsai CW,
    14. Bau DT
    : Contribution of caspase-8 genotypes to colorectal cancer risk in Taiwan. Anticancer Res 39: 2791-2797, 2019. PMID: 31177115. DOI: 10.21873/anticanres.13406
    OpenUrlAbstract/FREE Full Text
    1. Yueh TC,
    2. Hung YW,
    3. Shih TC,
    4. Wu CN,
    5. Wang SC,
    6. Lai YL,
    7. Hsu SW,
    8. Wu MH,
    9. Fu CK,
    10. Wang YC,
    11. Ke TW,
    12. Chang WS,
    13. Tsai CW,
    14. Bau DT
    : Contribution of murine double minute 2 genotypes to colorectal cancer risk in Taiwan. Cancer Genomics Proteomics 15: 405-411, 2018. PMID: 30194081. DOI: 10.21873/cgp.20099
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Yueh TC,
    2. Wu CN,
    3. Hung YW,
    4. Chang WS,
    5. Fu CK,
    6. Pei JS,
    7. Wu MH,
    8. Lai YL,
    9. Lee YM,
    10. Yen ST,
    11. Li HT,
    12. Tsai CW,
    13. Bau DT
    : The Contribution of MMP-7 genotypes to colorectal cancer susceptibility in Taiwan. Cancer Genomics Proteomics 15: 207-212, 2018. PMID: 29695403. DOI: 10.21873/cgp.20079
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Lin KM,
    2. Yang MD,
    3. Tsai CW,
    4. Chang WS,
    5. Hsiao CL,
    6. Jeng LB,
    7. Yueh TC,
    8. Lee MC,
    9. Bau DT
    : The role of MTHFR genotype in colorectal cancer susceptibility in Taiwan. Anticancer Res 38: 2001-2006, 2018. PMID: 29599316. DOI: 10.21873/anticanres.12438
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Lee CH,
    2. Cheng SC,
    3. Tung HY,
    4. Chang SC,
    5. Ching CY,
    6. Wu SF
    : The risk factors affecting survival in colorectal cancer in Taiwan. Iran J Public Health 47: 519-530, 2018. PMID: 29900136.
    OpenUrl
  13. ↵
    1. Migliore L,
    2. Migheli F,
    3. Spisni R,
    4. Coppede F
    : Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011: 792362, 2011. PMID: 21490705. DOI: 10.1155/2011/792362
    OpenUrlCrossRefPubMed
  14. ↵
    1. Otani K,
    2. Ishihara S,
    3. Yamaguchi H,
    4. Murono K,
    5. Yasuda K,
    6. Nishikawa T,
    7. Tanaka T,
    8. Kiyomatsu T,
    9. Hata K,
    10. Kawai K,
    11. Nozawa H,
    12. Watanabe T
    : Adiponectin and colorectal cancer. Surg Today 47: 151-158, 2017. PMID: 27061803. DOI: 10.1007/s00595-016-1334-4
    OpenUrl
  15. ↵
    1. Liu L,
    2. Zhong R,
    3. Wei S,
    4. Yin JY,
    5. Xiang H,
    6. Zou L,
    7. Chen W,
    8. Chen JG,
    9. Zheng XW,
    10. Huang LJ,
    11. Zhu BB,
    12. Chen Q,
    13. Duan SY,
    14. Rui R,
    15. Yang BF,
    16. Sun JW,
    17. Xie DS,
    18. Xu YH,
    19. Miao XP,
    20. Nie SF
    : Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. PLoS One 6: e27301, 2011. PMID: 22087284. DOI: 10.1371/journal.pone.0027301
    OpenUrlCrossRefPubMed
  16. ↵
    1. Aleksandrova K,
    2. Jenab M,
    3. Bueno-de-Mesquita HB,
    4. Fedirko V,
    5. Kaaks R,
    6. Lukanova A,
    7. van Duijnhoven FJ,
    8. Jansen E,
    9. Rinaldi S,
    10. Romieu I,
    11. Ferrari P,
    12. Murphy N,
    13. Gunter MJ,
    14. Riboli E,
    15. Westhpal S,
    16. Overvad K,
    17. Tjonneland A,
    18. Halkjaer J,
    19. Boutron-Ruault MC,
    20. Dossus L,
    21. Racine A,
    22. Trichopoulou A,
    23. Bamia C,
    24. Orfanos P,
    25. Agnoli C,
    26. Palli D,
    27. Panico S,
    28. Tumino R,
    29. Vineis P,
    30. Peeters PH,
    31. Duell EJ,
    32. Molina-Montes E,
    33. Quiros JR,
    34. Dorronsoro M,
    35. Chirlaque MD,
    36. Barricarte A,
    37. Ljuslinder I,
    38. Palmqvist R,
    39. Travis RC,
    40. Khaw KT,
    41. Wareham N,
    42. Pischon T,
    43. Boeing H
    : Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Epidemiol 29: 261-275, 2014. PMID: 24791703. DOI: 10.1007/s10654-014-9901-8
    OpenUrlCrossRefPubMed
  17. ↵
    1. Sveen A,
    2. Kopetz S,
    3. Lothe RA
    : Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 17: 11-32, 2020. PMID: 31289352. DOI: 10.1038/s41571-019-0241-1
    OpenUrl
  18. ↵
    1. Ishikawa M,
    2. Kitayama J,
    3. Kazama S,
    4. Hiramatsu T,
    5. Hatano K,
    6. Nagawa H
    : Plasma adiponectin and gastric cancer. Clin Cancer Res 11: 466-472, 2005. PMID: 15701829.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Stolzenberg-Solomon RZ,
    2. Weinstein S,
    3. Pollak M,
    4. Tao Y,
    5. Taylor PR,
    6. Virtamo J,
    7. Albanes D
    : Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 168: 1047-1055, 2008. PMID: 18801887. DOI: 10.1093/aje/kwn221
    OpenUrlCrossRefPubMed
  20. ↵
    1. Macis D,
    2. Gandini S,
    3. Guerrieri-Gonzaga A,
    4. Johansson H,
    5. Magni P,
    6. Ruscica M,
    7. Lazzeroni M,
    8. Serrano D,
    9. Cazzaniga M,
    10. Mora S,
    11. Feroce I,
    12. Pizzamiglio M,
    13. Sandri MT,
    14. Gulisano M,
    15. Bonanni B,
    16. Decensi A
    : Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol 30: 151-157, 2012. PMID: 22162577. DOI: 10.1200/JCO.2011.35.2237
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Soliman PT,
    2. Cui X,
    3. Zhang Q,
    4. Hankinson SE,
    5. Lu KH
    : Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. Am J Obstet Gynecol 204: 167 e161-165, 2011. PMID: 21047616. DOI: 10.1016/j.ajog.2010.08.045
    OpenUrl
  22. ↵
    1. Chen MW,
    2. Ye S,
    3. Zhao LL,
    4. Wang SY,
    5. Li YX,
    6. Yu CJ,
    7. Xie HJ,
    8. Wang YM
    : Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol 29: 3129-3135, 2012. PMID: 22752603. DOI: 10.1007/s12032-012-0280-2
    OpenUrlCrossRefPubMed
  23. ↵
    1. Dalamaga M,
    2. Migdalis I,
    3. Fargnoli JL,
    4. Papadavid E,
    5. Bloom E,
    6. Mitsiades N,
    7. Karmaniolas K,
    8. Pelecanos N,
    9. Tseleni-Balafouta S,
    10. Dionyssiou-Asteriou A,
    11. Mantzoros CS
    : Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control 20: 625-633, 2009. PMID: 19051043. DOI: 10.1007/s10552-008-9273-z
    OpenUrlCrossRefPubMed
  24. ↵
    1. Vansaun MN
    : Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res 19: 1926-1932, 2013. PMID: 23355630. DOI: 10.1158/1078-0432.CCR-12-0930
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Khandekar MJ,
    2. Cohen P,
    3. Spiegelman BM
    : Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 11: 886-895, 2011. PMID: 22113164. DOI: 10.1038/nrc3174
    OpenUrlCrossRefPubMed
  26. ↵
    1. Zemanova M,
    2. Stankova B,
    3. Usiakova Z,
    4. Tvrzicka E,
    5. Pazdro A,
    6. Petruzelka L,
    7. Zeman M
    : Serum adiponectin relates to shortened overall survival in men with squamous cell esophageal cancer treated with preoperative concurrent chemoradiotherapy: a pilot study. Med Sci Monit 20: 2351-2357, 2014. PMID: 25408239. DOI: 10.12659/MSM.891088
    OpenUrl
  27. ↵
    1. Gupta AC,
    2. Misra R,
    3. Sakhuja P,
    4. Singh Y,
    5. Basir SF,
    6. Sarin SK
    : Association of adiponectin gene functional polymorphisms (-11377C/G and +45T/G) with nonalcoholic fatty liver disease. Gene 496: 63-67, 2012. PMID: 22269154. DOI: 10.1016/j.gene.2011.12.023
    OpenUrl
  28. ↵
    1. Zhou L,
    2. Xi B,
    3. Wei Y,
    4. Pan H,
    5. Yang W,
    6. Shen W,
    7. Li Y,
    8. Cai J,
    9. Tang H
    : Association between adiponectin gene polymorphisms and coronary artery disease across different populations. Thromb Res 130: 52-57, 2012. PMID: 22261475. DOI: 10.1016/j.thromres.2011.12.028
    OpenUrlCrossRefPubMed
  29. ↵
    1. Han LY,
    2. Wu QH,
    3. Jiao ML,
    4. Hao YH,
    5. Liang LB,
    6. Gao LJ,
    7. Legge DG,
    8. Quan H,
    9. Zhao MM,
    10. Ning N,
    11. Kang Z,
    12. Sun H
    : Associations between single-nucleotide polymorphisms (+45T>G, +276G>T, -11377C>G, -11391G>A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 54: 2303-2314, 2011. PMID: 21638131. DOI: 10.1007/s00125-011-2202-9
    OpenUrlCrossRefPubMed
  30. ↵
    1. Siitonen N,
    2. Pulkkinen L,
    3. Lindstrom J,
    4. Kolehmainen M,
    5. Eriksson JG,
    6. Venojarvi M,
    7. Ilanne-Parikka P,
    8. Keinanen-Kiukaanniemi S,
    9. Tuomilehto J,
    10. Uusitupa M
    : Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med Genet 12: 5, 2011. PMID: 21219602. DOI: 10.1186/1471-2350-12-5
    OpenUrlCrossRefPubMed
  31. ↵
    1. Melistas L,
    2. Mantzoros CS,
    3. Kontogianni M,
    4. Antonopoulou S,
    5. Ordovas JM,
    6. Yiannakouris N
    : Association of the +45T>G and +276G>T polymorphisms in the adiponectin gene with insulin resistance in nondiabetic Greek women. Eur J Endocrinol 161: 845-852, 2009. PMID: 19755407. DOI: 10.1530/EJE-09-0492
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. He B,
    2. Pan Y,
    3. Zhang Y,
    4. Bao Q,
    5. Chen L,
    6. Nie Z,
    7. Gu L,
    8. Xu Y,
    9. Wang S
    : Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population. BMC Med Genet 12: 94, 2011. PMID: 21749709. DOI: 10.1186/1471-2350-12-94
    OpenUrlPubMed
  33. ↵
    1. Song M,
    2. Gong J,
    3. Giovannucci EL,
    4. Berndt SI,
    5. Brenner H,
    6. Chang-Claude J,
    7. Curtis KR,
    8. Harrison TA,
    9. Hoffmeister M,
    10. Hsu L,
    11. Jiao S,
    12. Le Marchand L,
    13. Potter JD,
    14. Schoen RE,
    15. Seminara D,
    16. Slattery ML,
    17. White E,
    18. Wu K,
    19. Ogino S,
    20. Fuchs CS,
    21. Hunter DJ,
    22. Tworoger SS,
    23. Hu FB,
    24. Rimm E,
    25. Jensen M,
    26. Peters U,
    27. Chan AT
    : Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer 137: 154-164, 2015. PMID: 25431318. DOI: 10.1002/ijc.29360
    OpenUrl
  34. ↵
    1. Gornick MC,
    2. Rennert G,
    3. Moreno V,
    4. Gruber SB
    : Adiponectin gene and risk of colorectal cancer. Br J Cancer 105: 562-564, 2011. PMID: 21829206. DOI: 10.1038/bjc.2011.259
    OpenUrlPubMed
  35. ↵
    1. Yang MD,
    2. Hsu YM,
    3. Kuo YS,
    4. Chen HS,
    5. Chang CL,
    6. Wu CN,
    7. Chang CH,
    8. Liao YM,
    9. Wang HC,
    10. Wang MF,
    11. Bau DT
    : Significant association of Ku80 single nucleotide polymorphisms with colorectal cancer susceptibility in Central Taiwan. Anticancer Res 29: 2239-2242, 2009. PMID: 19528488.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Yang MD,
    2. Tsai RY,
    3. Liu CS,
    4. Chang CH,
    5. Wang HC,
    6. Tsou YA,
    7. Wang CH,
    8. Lin CC,
    9. Shyue SK,
    10. Bau DT
    : Association of Caveolin-1 polymorphisms with colorectal cancer susceptibility in Taiwan. World J Gastrointest Oncol 2: 326-331, 2010. PMID: 21160894. DOI: 10.4251/wjgo.v2.i8.326
    OpenUrlPubMed
  37. ↵
    1. Hsu PC,
    2. Chen CC,
    3. Tzeng HE,
    4. Hsu YN,
    5. Kuo CC,
    6. Lin ML,
    7. Chang WS,
    8. Wang YC,
    9. Tsai CW,
    10. Pei JS,
    11. Bau DT
    : HOGG1 rs1052133 genotypes and risk of childhood acute lymphoblastic leukemia in a Taiwanese population. In Vivo 33: 1081-1086, 2019. PMID: 31280195. DOI: 10.21873/invivo.11576.
    OpenUrlAbstract/FREE Full Text
    1. Shih LC,
    2. Tsai CW,
    3. Sun KT,
    4. Hsu HM,
    5. Shen TC,
    6. Tsai YT,
    7. Chang WS,
    8. Lin ML,
    9. Wang YC,
    10. Gong CL,
    11. Bau DT
    : Association of caspase-8 genotypes with oral cancer risk in Taiwan. In Vivo 33: 1151-1156, 2019. PMID: 31280204. DOI: 10.21873/invivo. 11585
    OpenUrlAbstract/FREE Full Text
    1. Hsu SW,
    2. Gong CL,
    3. Hsu HM,
    4. Chao CC,
    5. Wang YC,
    6. Chang WS,
    7. Tsai YT,
    8. Shih LC,
    9. Tsai CW,
    10. Bau DT
    : Contribution of matrix metalloproteinase-2 promoter genotypes to nasopharyngeal cancer susceptibility and metastasis in Taiwan. Cancer Genomics Proteomics 16: 287-292, 2019. PMID: 31243109. DOI: 10.21873/cgp.20133
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Hu PS,
    2. Wang YC,
    3. Liao CH,
    4. Hsia NY,
    5. Wu MF,
    6. Yang JS,
    7. Yu CC,
    8. Chang WS,
    9. Bau DT,
    10. Tsai CW
    : The association of MMP7 genotype with pterygium. In Vivo 34: 51-56, 2020. PMID: 31882462. DOI: 10.21873/invivo.11744
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Chen PC,
    2. Lee JC,
    3. Wang JD
    : Estimation of life-year loss and lifetime costs for different stages of colon adenocarcinoma in Taiwan. PLoS One 10: e0133755, 2015. PMID: 26207912. DOI: 10.1371/journal.pone.0133755
    OpenUrl
    1. Beckmann KR,
    2. Bennett A,
    3. Young GP,
    4. Cole SR,
    5. Joshi R,
    6. Adams J,
    7. Singhal N,
    8. Karapetis C,
    9. Wattchow D,
    10. Roder D
    : Sociodemographic disparities in survival from colorectal cancer in South Australia: a population-wide data linkage study. BMC Health Serv Res 16: 24, 2016. PMID: 26792195. DOI: 10.1186/s12913-016-1263-3
    OpenUrl
    1. Perron L,
    2. Daigle JM,
    3. Vandal N,
    4. Guertin MH,
    5. Brisson J
    : Characteristics affecting survival after locally advanced colorectal cancer in Quebec. Curr Oncol 22: e485-492, 2015. PMID: 26715887. DOI: 10.3747/co.22.2692
    OpenUrl
  40. ↵
    1. Wang R,
    2. Wang MJ,
    3. Ping J
    : Clinicopathological features and survival outcomes of colorectal cancer in young versus elderly: A population-based cohort study of SEER 9 registries data (1988-2011). Medicine (Baltimore) 94: e1402, 2015. PMID: 26334895. DOI: 10.1097/MD.0000000000001402
    OpenUrlCrossRefPubMed
  41. ↵
    1. Calle EE,
    2. Kaaks R
    : Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579-591, 2004. PMID: 15286738. DOI: 10.1038/nrc1408
    OpenUrlCrossRefPubMed
    1. Le Marchand L,
    2. Wilkens LR,
    3. Kolonel LN,
    4. Hankin JH,
    5. Lyu LC
    : Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 57: 4787-4794, 1997. PMID: 9354440.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Oxentenko AS,
    2. Bardia A,
    3. Vierkant RA,
    4. Wang AH,
    5. Anderson KE,
    6. Campbell PT,
    7. Sellers TA,
    8. Folsom AR,
    9. Cerhan JR,
    10. Limburg PJ
    : Body size and incident colorectal cancer: a prospective study of older women. Cancer Prev Res (Phila) 3: 1608-1620, 2010. PMID: 20719902. DOI: 10.1158/1940-6207.CAPR-10-0116
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Ouchi N,
    2. Kihara S,
    3. Arita Y,
    4. Maeda K,
    5. Kuriyama H,
    6. Okamoto Y,
    7. Hotta K,
    8. Nishida M,
    9. Takahashi M,
    10. Nakamura T,
    11. Yamashita S,
    12. Funahashi T,
    13. Matsuzawa Y
    : Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100: 2473-2476, 1999. PMID: 10982546. DOI: 10.1161/01.cir.102.11.1296
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Meilleur KG,
    2. Doumatey A,
    3. Huang H,
    4. Charles B,
    5. Chen G,
    6. Zhou J,
    7. Shriner D,
    8. Adeyemo A,
    9. Rotimi C
    : Circulating adiponectin is associated with obesity and serum lipids in West Africans. J Clin Endocrinol Metab 95: 3517-3521, 2010. PMID: 20382687. DOI: 10.1210/jc.2009-2765
    OpenUrlCrossRefPubMed
  45. ↵
    1. Barresi V,
    2. Tuccari G,
    3. Barresi G
    : Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density. Pathology 41: 533-538, 2009. PMID: 19900101. DOI: 10.1080/00313020903071553
    OpenUrl
  46. ↵
    1. Wei EK,
    2. Giovannucci E,
    3. Fuchs CS,
    4. Willett WC,
    5. Mantzoros CS
    : Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97: 1688-1694, 2005. PMID: 16288122. DOI: 10.1093/jnci/dji376
    OpenUrlCrossRefPubMed
  47. ↵
    1. Otake S,
    2. Takeda H,
    3. Fujishima S,
    4. Fukui T,
    5. Orii T,
    6. Sato T,
    7. Sasaki Y,
    8. Nishise S,
    9. Kawata S
    : Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol 16: 1252-1257, 2010. PMID: 20222170. DOI: 10.3748/wjg.v16.i10.1252
    OpenUrlCrossRefPubMed
  48. ↵
    1. Nakajima TE,
    2. Yamada Y,
    3. Hamano T,
    4. Furuta K,
    5. Matsuda T,
    6. Fujita S,
    7. Kato K,
    8. Hamaguchi T,
    9. Shimada Y
    : Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 101: 1286-1291, 2010. PMID: 20331631. DOI: 10.1111/j.1349-7006.2010.01518.x
    OpenUrlCrossRefPubMed
  49. ↵
    1. Fenton JI,
    2. Birmingham JM,
    3. Hursting SD,
    4. Hord NG
    : Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer 122: 2437-2445, 2008. PMID: 18338750. DOI: 10.1002/ijc.23436
    OpenUrlCrossRefPubMed
  50. ↵
    1. Qi L,
    2. Doria A,
    3. Manson JE,
    4. Meigs JB,
    5. Hunter D,
    6. Mantzoros CS,
    7. Hu FB
    : Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes 55: 1512-1516, 2006. PMID: 16644713. DOI: 10.2337/db05-1520
    OpenUrlAbstract/FREE Full Text
    1. Heid IM,
    2. Wagner SA,
    3. Gohlke H,
    4. Iglseder B,
    5. Mueller JC,
    6. Cip P,
    7. Ladurner G,
    8. Reiter R,
    9. Stadlmayr A,
    10. Mackevics V,
    11. Illig T,
    12. Kronenberg F,
    13. Paulweber B
    : Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes 55: 375-384, 2006. PMID: 16443770. DOI: 10.2337/diabetes.55.02.06.db05-0747
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Menzaghi C,
    2. Ercolino T,
    3. Di Paola R,
    4. Berg AH,
    5. Warram JH,
    6. Scherer PE,
    7. Trischitta V,
    8. Doria A
    : A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51: 2306-2312, 2002. PMID: 12086965. DOI: 10.2337/diabetes.51.7.2306
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Ong KL,
    2. Li M,
    3. Tso AW,
    4. Xu A,
    5. Cherny SS,
    6. Sham PC,
    7. Tse HF,
    8. Lam TH,
    9. Cheung BM,
    10. Lam KS,
    11. Investigators of the Hong Kong Cardiovascular Risk Factor Prevalence S
    : Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese. Eur J Endocrinol 163: 251-257, 2010. PMID: 20516205. DOI: 10.1530/EJE-10-0251
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Pechlivanis S,
    2. Bermejo JL,
    3. Pardini B,
    4. Naccarati A,
    5. Vodickova L,
    6. Novotny J,
    7. Hemminki K,
    8. Vodicka P,
    9. Forsti A
    : Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol 160: 933-940, 2009. PMID: 19273568. DOI: 10.1530/EJE-09-0039
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Pham NM,
    2. Mizoue T,
    3. Tanaka K,
    4. Tsuji I,
    5. Tamakoshi A,
    6. Matsuo K,
    7. Wakai K,
    8. Nagata C,
    9. Inoue M,
    10. Tsugane S,
    11. Sasazuki S,
    12. Research Group for the D and Evaluation of Cancer Prevention Strategies in J
    : Meat consumption and colorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 44: 641-650, 2014. PMID: 24842864. DOI: 10.1093/jjco/hyu061
    OpenUrlCrossRefPubMed
  55. ↵
    1. Gialamas SP,
    2. Petridou ET,
    3. Tseleni-Balafouta S,
    4. Spyridopoulos TN,
    5. Matsoukis IL,
    6. Kondi-Pafiti A,
    7. Zografos G,
    8. Mantzoros CS
    : Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 60: 1530-1538, 2011. PMID: 21632074. DOI: 10.1016/j.metabol.2011.03.020
    OpenUrlCrossRefPubMed
  56. ↵
    1. Su YX,
    2. Deng HC,
    3. Zhang MX,
    4. Long J,
    5. Peng ZG
    : Adiponectin inhibits PDGF-induced mesangial cell proliferation: regulation of mammalian target of rapamycin-mediated survival pathway by adenosine 5-monophosphate-activated protein kinase. Horm Metab Res 44: 21-27, 2012. PMID: 22105511. DOI: 10.1055/s-0031-1295404
    OpenUrlPubMed
  57. ↵
    1. Cheng SP,
    2. Liu CL,
    3. Hsu YC,
    4. Chang YC,
    5. Huang SY,
    6. Lee JJ
    : Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys 65: 203-210, 2013. PMID: 22907586. DOI: 10.1007/s12013-012-9419-1
    OpenUrlCrossRefPubMed
  58. ↵
    1. Yamauchi T,
    2. Kamon J,
    3. Ito Y,
    4. Tsuchida A,
    5. Yokomizo T,
    6. Kita S,
    7. Sugiyama T,
    8. Miyagishi M,
    9. Hara K,
    10. Tsunoda M,
    11. Murakami K,
    12. Ohteki T,
    13. Uchida S,
    14. Takekawa S,
    15. Waki H,
    16. Tsuno NH,
    17. Shibata Y,
    18. Terauchi Y,
    19. Froguel P,
    20. Tobe K,
    21. Koyasu S,
    22. Taira K,
    23. Kitamura T,
    24. Shimizu T,
    25. Nagai R,
    26. Kadowaki T
    : Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769, 2003. PMID: 12802337. DOI: 10.1038/nature01705
    OpenUrlCrossRefPubMed
  59. ↵
    1. Turer AT,
    2. Scherer PE
    : Adiponectin: mechanistic insights and clinical implications. Diabetologia 55: 2319-2326, 2012. PMID: 22688349. DOI: 10.1007/s00125-012-2598-x
    OpenUrlCrossRefPubMed
  60. ↵
    1. Ou Y,
    2. Chen P,
    3. Zhou Z,
    4. Li C,
    5. Liu J,
    6. Tajima K,
    7. Guo J,
    8. Cao J,
    9. Wang H
    : Associations between variants on ADIPOQ and ADIPOR1 with colorectal cancer risk: a Chinese case-control study and updated meta-analysis. BMC Med Genet 15: 137, 2014. PMID: 25516230. DOI: 10.1186/s12881-014-0137-y
    OpenUrl
  61. ↵
    1. Lopez-Bermejo A,
    2. Botas-Cervero P,
    3. Ortega-Delgado F,
    4. Delgado E,
    5. Garcia-Gil MM,
    6. Funahashi T,
    7. Ricart W,
    8. Fernandez-Real JM
    : Association of ADIPOR2 with liver function tests in type 2 diabetic subjects. Obesity (Silver Spring) 16: 2308-2313, 2008. PMID: 18719649. DOI: 10.1038/oby.2008.344
    OpenUrlPubMed
    1. Ye L,
    2. Zhang ZY,
    3. Du WD,
    4. Schneider ME,
    5. Qiu Y,
    6. Zhou Y,
    7. Zhou FS,
    8. Zuo XB,
    9. Chen G,
    10. Ma XL,
    11. Xia HZ,
    12. Xu S,
    13. Wu JF,
    14. Xu HY,
    15. Zhang XJ
    : Genetic analysis of ADIPOQ variants and gastric cancer risk: a hospital-based case-control study in China. Med Oncol 30: 658, 2013. PMID: 23884578. DOI: 10.1007/s12032-013-0658-9
    OpenUrl
  62. ↵
    1. Dhillon PK,
    2. Penney KL,
    3. Schumacher F,
    4. Rider JR,
    5. Sesso HD,
    6. Pollak M,
    7. Fiorentino M,
    8. Finn S,
    9. Loda M,
    10. Rifai N,
    11. Mucci LA,
    12. Giovannucci E,
    13. Stampfer MJ,
    14. Ma J
    : Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 20: 2618-2627, 2011. PMID: 21960694. DOI: 10.1158/1055-9965.EPI-11-0434
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Li P,
    2. Liu H,
    3. Li C,
    4. Yang B,
    5. Kong Q,
    6. Zheng W,
    7. Li B,
    8. Jia B
    : An updated meta-analysis of the association between ADIPOQ rs2241766 polymorphism and colorectal cancer. Tumour Biol 35: 2491-2496, 2014. PMID: 24293390. DOI: 10.1007/s13277-013-1329-3
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (3)
Anticancer Research
Vol. 40, Issue 3
March 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Association of Adiponectin Genotypes With Colorectal Cancer Susceptibility in Taiwan
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Association of Adiponectin Genotypes With Colorectal Cancer Susceptibility in Taiwan
YI-CHIH HUNG, WEN-SHIN CHANG, AN-KUO CHOU, JEN-SHENG PEI, MEI-DUE YANG, HORNG-REN YANG, TA-MING YANG, YUN-CHI WANG, YU-CHEN HSIAU, CHOU-PIN CHEN, CHOU-CHEN CHEN, CHIEN-CHIH YU, CHIA-WEN TSAI, DA-TIAN BAU
Anticancer Research Mar 2020, 40 (3) 1297-1306; DOI: 10.21873/anticanres.14071

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Association of Adiponectin Genotypes With Colorectal Cancer Susceptibility in Taiwan
YI-CHIH HUNG, WEN-SHIN CHANG, AN-KUO CHOU, JEN-SHENG PEI, MEI-DUE YANG, HORNG-REN YANG, TA-MING YANG, YUN-CHI WANG, YU-CHEN HSIAU, CHOU-PIN CHEN, CHOU-CHEN CHEN, CHIEN-CHIH YU, CHIA-WEN TSAI, DA-TIAN BAU
Anticancer Research Mar 2020, 40 (3) 1297-1306; DOI: 10.21873/anticanres.14071
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Contribution of Matrix Metalloproteinase-1 Genotypes to Colorectal Cancer in Taiwan
  • Google Scholar

More in this TOC Section

  • 5-Azacytidine (5-aza) Induces p53-associated Cell Death Through Inhibition of DNA Methyltransferase Activity in Hep3B and HT-29 Cells
  • Prognostic Value of WNT1, NOTCH1, PDGFRβ, and CXCR4 in Oral Squamous Cell Carcinoma
  • Hypoxia-adapted Multiple Myeloma Stem Cells Resist γδ-T-Cell-mediated Killing by Modulating the Mevalonate Pathway
Show more Experimental Studies

Similar Articles

Keywords

  • ADIPOQ
  • colorectal cancer
  • Genotype
  • polymorphism
  • Taiwan
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire